Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance
In previous Russian AML multicenter studies it was shown that escalation of ARA-C dose (from
5,6 g to 72 g in 4 induction/consolidation courses) in parallel with anthracyclines dose
reduction (from 630 mg/m2 to 285 mg/m2)did not improve survival, but decreased feasibility.
In the ongoing trial we try to learn whether anthracyclines dose escalation (up to 720-660
mg m2) will or will not equivalise the standard (5,6 g in 4 induction/consolidation courses)
and high (14,8 g) ARA-C doses.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Valeriy G Savchenko
National Research center of Hematology
Russia: Ministry of Health of the Russian Federation